ANA Ananda Developments Plc

9^th December 2024

ANANDA DEVELOPMENTS PLC 

("Ananda" or the "Company") 

Further Promising Results for MRX1 treating Heart Failure

Ananda Developments plc (AQSE: ANA), a company focused on the development of cannabinoid therapies for the treatment of a range of complex conditions, is pleased to announce the further results from its research into the use of MRX1, one of its investigative CBD medicines, for treating heart failure.

These results build on the previous work which demonstrated MRX1's ability to improve cardiac and lung weights, reduce fibrosis, and enhance heart function in a mouse model of heart failure with preserved ejection fraction (HFpEF), which were announced on 26 June 2024.These new findings have further demonstrated MRX1's potential as a treatment for HFpEF.

Highlights:

·    MRX1 treatment resulted in a significant reduction in blood plasma levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, indicating reduced cardiac stress and improved heart function

·    NT-proBNP is a recommended clinical biomarker widely-(a measurable molecule or characteristic that indicates the presence and/or severity of a specific disease or condition) used in the diagnosis and management of heart failure

·    This biomarker will serve as a key measure in future human clinical trials to assess the efficacy of MRX1 in treating heart failure

·    Improvements were observed across molecular markers of fibrosis, cardiac stress, and oxidative damage, supporting the broader cardioprotective effects of MRX1.

·    These findings will be used to support Ananda's existing MRX1 patent application

·    To view an additional video by Jeremy Sturgess-Smith, Finance Director of Ananda Developments Plc, and the chance to have your questions directly answered by the management team, please head to our interactive investor hub via: https://investors.anandadevelopments.com/link/aP3bQr

Ananda's CEO, Melissa Sturgess commented: "We are delighted to share these new findings. The demonstration by MRX1 that it significantly reduced NT-proBNP, a marker of heart failure, in mice provides compelling evidence of MRX1's potential to address the underlying mechanisms of heart failure. As NT-proBNP is a key biomarker recommended by NICE, it will also serve as a critical measure of efficacy in any future human trials we can commission. Ananda is committed to advancing this research into transformative therapies for patients worldwide." 

The research was conducted by Dr. Nadine Godsman and Dr. Sarah Walsh at Robert Gordon University ("RGU"), Aberdeen, under the guidance of Professor Cherry Wainwright, a member of Ananda's Scientific Advisory Board. In the study, which lasted for 7 weeks, mice were treated with the high fat diet (L-NAME) or a control diet for the entire 7 week period. Two thirds of the high fat diet mice were then dosed with either MRX1 or RGU MRX1 for weeks 6&7 of the study.

HFpEF accounts for 50% of all heart failure cases and has limited treatment options. This study strengthens the evidence that MRX1 could serve as a valuable therapeutic for this challenging condition.

-Ends-

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: investors.anandadevelopments.com

·              Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·              LinkedIn: https://www.linkedin.com/company/anadevelopments/   

·              Twitter: https://twitter.com/AnandaPlc

·              Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor

-Ends-  

The Directors of the Company accept responsibility for the contents of this announcement.  

About Ananda Developments  

Ananda is an AQSE-listed life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com

Market Abuse Regulation (MAR) Disclosure  

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.  

https://investors.anandadevelopments.com/link/aP3bQr